Abstract:ABSTRACTAttenuatedSalmonella entericaserovar Typhimurium has been used for targeted delivery of recombinant antigens to gut- and nose-associated lymphoid tissues. Contradictory reports have described the effect of preexisting immunity to the antigen delivery vehicle. We decided to examine this discrepancy by studying the effect of immunizing mice by the intranasal (i.n.) route withSalmonellaexpressing an insoluble protein and to study the ability to augment recall responses by boosting with eitherSalmonella-expressed protein or purified soluble protein alone. The glucan-binding domain (GLU) of the enzyme glucosyltransferase (GTF), which is an important virulence factor ofStreptococcus mutans, was recombinantly expressed in the insoluble phase inS. entericaserovar Typhimurium, and the immunogenicity of this construct was studied in mice. We examined the induction of primary immune responses by insoluble GLU polypeptide delivered inSalmonellaat week 1 (groups 1 and 2) and recall responses after a week 15 boost with eitherSalmonellaexpressing GLU (group 1) or purified GLU polypeptide (groups 2 and 3). Group 4 served as the control and received phosphate-buffered saline alone by the i.n. route. Significant anti-GLU serum immunoglobulin G (IgG) levels were seen in groups 1, 2, and 3 at week 18 (P< 0.001), i.e., 3 weeks after the booster immunization. Mice in group 2, who receivedSalmonellafollowed by GLU, had the highest GLU-specific IgG levels among all groups. The serum IgG levels persisted in all responding groups for at least 7 weeks after the boost (week 22). The IgG2a/IgG1 subclass ratio of serum anti-GLU antibodies in group 1 significantly increased after the boost. These results support the induction of a type 1-like immune response to GLU after primary and booster immunizations withSalmonellaexpressing GLU. On the other hand, group 2 mice, which receivedSalmonellaexpressing GLU as the primary dose and soluble protein as the booster dose, exhibited a shift from a type 1-like to a more type 2-like immune response to GLU following the boost. These results indicate thatS. entericaserovar Typhimurium is an excellent delivery vehicle for the insoluble and recombinantly expressed GLU of GTF and that this construct was especially effective in priming the host for a secondary response to soluble GLU polypeptide.

Contribution of a Streptococcus mutans antigen expressed by a Salmonella vector vaccine in dendritic cell activation

Role of Toll-like receptors in host responses to a virulence antigen of Streptococcus mutans expressed by a recombinant, attenuated Salmonella vector vaccine

Immunogenicity of Salmonella Vector Vaccines Expressing SBR of Streptococcus Mutans under the Control of a T7-nirB (dual) Promoter System

Enhanced Immunogenicity of a Genetic Chimeric Protein Consisting of Two Virulence Antigens of Streptococcus Mutans and Protection Against Infection.

Effect of Attenuated Salmonella Enterica Serovar Typhimurium Expressing A Streptococcus Mutans Antigen on Secondary Responses to the Cloned Protein

Regulated Delayed Shigella flexneri 2a O-antigen Synthesis in Live Recombinant Salmonella enterica Serovar Typhimurium Induces Comparable Levels of Protective Immune Responses with Constitutive Antigen Synthesis System.

MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen

Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen

Vaccine-induced inflammation and inflammatory monocytes promote CD4+ T cell-dependent immunity against murine salmonellosis

Immunity to Salmonella from a dendritic point of view

Palmitoylation State Impacts Induction of Innate and Acquired Immunity by the Salmonella Enterica Serovar Typhimurium Msbb Mutant

Reversible Synthesis of Colanic Acid and O-antigen Polysaccharides in Salmonella Typhimurium Enhances Induction of Cross-Immune Responses and Provides Protection Against Heterologous Salmonella Challenge.

Oral immunization of mice with attenuated Salmonella typhimurium containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus

Evaluation of Efficacy, Biodistribution and Safety of Antibiotic-Free Plasmid Encoding Somatostatin Genes Delivered by Attenuated Salmonella Enterica Serovar Choleraesuis

An oral recombinant Salmonella enterica serovar Typhimurium mutant elicits systemic antigen-specific CD8+ T cell cytokine responses in mice

Effect of Deletion of Gene Cluster Involved in Synthesis of Enterobacterial Common Antigen on Virulence and Immunogenicity of Live Attenuated Salmonella Vaccine when Delivering Heterologous Streptococcus Pneumoniae Antigen PspA

Attenuated Streptococcus pneumoniae vaccine candidate SPY1 promotes dendritic cell activation and drives a Th1/Th17 response

Effect of Different Adjuvants on Protection and Side-Effects Induced by Helicobacter suis Whole-Cell Lysate Vaccination

Immunogenicity and cross-protective efficacy induced by delayed attenuated Salmonella with regulated length of lipopolysaccharide in mice

Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a.

Antigen-encapsulating host extracellular vesicles derived from Salmonella-infected cells stimulate pathogen-specific Th1-type responses in vivo